Post-COVID-19 Resurgence of Mycoplasma pneumoniae Infections Among Children in China: A Comprehensive Genomic Analysis

Strategic Insights -

Research on the resurgence of Mycoplasma pneumoniae infections among children in China following the COVID-19 pandemic has revealed significant insights into the genetic mechanisms driving this outbreak. According to a report from the China National Center for Bioinformation, whole-genome sequencing of 169 isolates from Beijing and Baoding collected before and after COVID-19 revealed a post-COVID-19 resurgence of infections among children, with infection rates peaking at 60%-70% in late 2023, higher than during the pandemic (10%-20%) and pre-pandemic (30%). Genomic analysis identified distinct genotypes, with T1-2 (4-5-7-2) dominating in Beijing, and both T1-2 and T2-2 (3-5-6-2) prevalent in Baoding.

Key Takeaways:

  • The post-COVID-19 resurgence of Mycoplasma pneumoniae infections among children in China has led to infection rates peaking at 60%-70% in late 2023, significantly higher than during the pandemic (10%-20%) and pre-pandemic (30%) rates.
  • Whole-genome sequencing revealed distinct genotypes, with T1-2 (4-5-7-2) dominating in Beijing, and both T1-2 and T2-2 (3-5-6-2) prevalent in Baoding.
  • Genomic analysis identified key genetic factors driving the outbreak, including near-100% macrolide resistance and increased prevalence of the 4-5-7-2 genotype, enriched in virulence and metabolism-related genes.
  • The study provides a comprehensive genomic analysis of the genetic factors driving the outbreak and offers insights into the outbreak causes and guides future prevention and control strategies.

Significant Genetic Factors:

  • Near-100% macrolide resistance in China warrants urgent changes in treatment policies.
  • Rising prevalence of the 4-5-7-2 genotype and its functional advantages require close monitoring.

Statistics:

  • 169 isolates were collected from Beijing and Baoding before and after COVID-19 for whole-genome sequencing.
  • Infection rates peaked at 60%-70% in late 2023, significantly higher than during the pandemic (10%-20%) and pre-pandemic (30%) rates.
  • 100% macrolide resistance was identified in the study, indicating urgent changes in treatment policies are needed.

Sources:

  • The Lancet Regional Health - Western Pacific (The Lancet Regional Health - Western Pacific, 2025; 59: 101578)
  • NewsRx (NewsRx. China National Center for Bioinformation Reports Findings in COVID-19 (Genetic factors driving the Mycoplasma pneumoniae outbreak among children post-COVID-19 in China: a whole genome analysis). Pediatrics Week. June 28, 2025; p 1.)